Precision BioSciences’ Partner TG Therapeutics Receives the US FDA’s IND Clearance to Advance Azer-Cel for Multiple Sclerosis
Shots:
- TG Therapeutics (Precision BioSciences’ partner) has received the US FDA’s IND approval to advance azercabtagene zapreleucel (azer-cel) into human studies as a treatment of progressive forms of multiple sclerosis
- Azer-cel, an allogeneic CAR T therapy, has been discovered by Precision BioSciences and will be investigated by TG Therapeutics under the P-I study, planned in H2’24
- Precision BioSciences licensed global rights of azer-cel to TG Therapeutics for autoimmune diseases and non-cancer indications in Jan 2024, for which it received $17.5M upfront & potential near-term payments, ~$288M clinical, regulatory & commercial milestones plus high-single-digit to low-double-digit royalties
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
